[go: up one dir, main page]

DE69733694D1 - Verwendung von proteinen aus der mk familie als hämatopoietischer faktor - Google Patents

Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Info

Publication number
DE69733694D1
DE69733694D1 DE69733694T DE69733694T DE69733694D1 DE 69733694 D1 DE69733694 D1 DE 69733694D1 DE 69733694 T DE69733694 T DE 69733694T DE 69733694 T DE69733694 T DE 69733694T DE 69733694 D1 DE69733694 D1 DE 69733694D1
Authority
DE
Germany
Prior art keywords
family
hematopoietic
csf
proteins
hematopoietic factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69733694T
Other languages
English (en)
Other versions
DE69733694T2 (de
Inventor
Makoto Kikuchi
Shinya Ikematsu
Munehiro Oda
Sadatoshi Sakuma
Takashi Muramatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Muramatsu Takashi Nagoya Aichi Jp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Application granted granted Critical
Publication of DE69733694D1 publication Critical patent/DE69733694D1/de
Publication of DE69733694T2 publication Critical patent/DE69733694T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0647Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • C12N2500/24Iron; Fe chelators; Transferrin
    • C12N2500/25Insulin-transferrin; Insulin-transferrin-selenium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/125Stem cell factor [SCF], c-kit ligand [KL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/14Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/22Colony stimulating factors (G-CSF, GM-CSF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69733694T 1996-07-10 1997-07-10 Verwendung von proteinen aus der mk familie als hämatopoietischer faktor Expired - Fee Related DE69733694T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP19853196 1996-07-10
JP19853196 1996-07-10
PCT/JP1997/002401 WO1998001151A1 (en) 1996-07-10 1997-07-10 Novel use of mk family as hematopoietic factor

Publications (2)

Publication Number Publication Date
DE69733694D1 true DE69733694D1 (de) 2005-08-11
DE69733694T2 DE69733694T2 (de) 2006-07-06

Family

ID=16392704

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733694T Expired - Fee Related DE69733694T2 (de) 1996-07-10 1997-07-10 Verwendung von proteinen aus der mk familie als hämatopoietischer faktor

Country Status (6)

Country Link
US (2) US6383480B1 (de)
EP (1) EP0937461B1 (de)
AT (1) ATE299030T1 (de)
CA (1) CA2260014A1 (de)
DE (1) DE69733694T2 (de)
WO (1) WO1998001151A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
AU756279B2 (en) 1997-07-14 2003-01-09 Medical Therapies Limited Agents comprising Midkine or its inhibitor as active ingredient
EP1147777A1 (de) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Kombination von Defibrotid und G-CSF und ihre Verwendung zur Aktivierung der hämatopoiestischen Vorläuferzellen
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
US20040042997A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of regenerating human tissue
US20040076620A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of repairing primate mammalian tissue
US20040043009A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of repairing primate mammalian tissue
US20040076605A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of regenerating human tissue
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
FR2853663B1 (fr) * 2003-04-14 2007-08-31 Aventis Pharma Sa Procede d'obtention de lignees de mastocytes a partir de tissus de porcs et procede de production de molecules de type heparine
JP4651282B2 (ja) 2004-01-21 2011-03-16 田辺三菱製薬株式会社 造血幹細胞及び造血前駆細胞の増幅方法
JP2008505650A (ja) * 2004-07-12 2008-02-28 ソリン・グループ・イタリア・ソシエタ・ア・レスポンサビリタ・リミタータ ヒト細胞を増殖させるための装置及び方法
EP1789552A2 (de) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Verfahren zur regulation der differenzierung und behandlung von multiplem myelom
JP4791770B2 (ja) * 2004-12-06 2011-10-12 株式会社セルシグナルズ 心筋障害又は心不全の治療もしくは予防組成物
US20070131375A1 (en) * 2005-12-09 2007-06-14 Husky Injection Molding Systems Ltd. Thixo-molding shot located downstream of blockage
WO2010036373A2 (en) * 2008-09-26 2010-04-01 Duke University Hematopoietic stem cell growth factor
EP2637672B1 (de) 2010-11-12 2018-08-22 Gentium S.r.l. Defibrotid zur prophylaxe und/oder behandlung von graft-versus-host-reaktion (gvhr)
CA2874960C (en) 2012-06-22 2021-05-18 Gentium S.P.A. Euglobulin-based method for determining the biological activity of defibrotide
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
EP3026122A1 (de) 2014-11-27 2016-06-01 Gentium S.p.A. Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868119A (en) 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
FI884877L (fi) * 1986-05-06 1988-10-21 Genetics Inst Produktion av m-csf.
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
FR2666477A1 (fr) 1990-08-31 1992-03-06 Sodern Tube neutronique a flux eleve.
WO1992006712A1 (en) 1990-10-12 1992-04-30 Amgen Inc. Megakaryocyte maturation factors
EP0584184A4 (en) * 1991-04-09 1995-12-27 Indiana University Foundation System and process for supporting hematopoietic cells
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
DE4240635C2 (de) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
AU8014694A (en) * 1993-10-07 1995-05-01 Systemix, Inc. Methods for analysis of human stem cells

Also Published As

Publication number Publication date
DE69733694T2 (de) 2006-07-06
AU733451B2 (en) 2001-05-17
ATE299030T1 (de) 2005-07-15
US6939669B2 (en) 2005-09-06
US6383480B1 (en) 2002-05-07
EP0937461B1 (de) 2005-07-06
CA2260014A1 (en) 1998-01-15
EP0937461A1 (de) 1999-08-25
WO1998001151A1 (en) 1998-01-15
AU3459397A (en) 1998-02-02
US20020132984A1 (en) 2002-09-19
EP0937461A4 (de) 2002-10-16

Similar Documents

Publication Publication Date Title
DE69733694D1 (de) Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
DE69816707D1 (de) Die Verwendung von Polyäther Alkohol und Hydrocarbylphenol enthaltenden Brennstoffzusatzzusammensetzungen
NO952398D0 (no) Pyrrolpyrimidiner som CRF antagonister
FI842829A0 (fi) Cykliska ureakondensat, behandlingskompositioner foer textilier och papper och nya cykliska ureafoereningar.
DE69917296D1 (de) Neue substituierte triazolverbindungen
ATE464373T1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
EP0900083A4 (de) Neue substituierte imidazolverbindungen
RU94044324A (ru) СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ СЛОЖНЫХ ЭФИРОВ ИЗОСЕРИНА С ИСПОЛЬЗОВАНИЕМ МЕТАЛАЛКОГОЛЯТОВ И β -ЛАКТАМОВ
MX9805499A (es) Compuestos de azacicloheptano y diazacicloheptano y ciclooctano sustituidos y su uso.
DE69315706D1 (de) Aminosubstituierte pyrazole mit crf antagonistischer aktivität
TR199901282T2 (xx) Heterosiklik olarak ikame edilmi� yeni benzamitler.
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
DE69529121D1 (de) Verwendung von CRF-Antagonisten
AU631312B2 (en) Muteins of the granulocyte colony stimulating factor (g-csf)
IT8448944A0 (it) Composizione contenente manganese e rame,combustibile che la contiene e relativo metodo per ridurre l'accensione di particelle di scarico
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
DE69006878D1 (de) Teilchenförmiger Reinigungsmittel-Zusatz, dessen Herstellung und Verwendung in Reinigungsmittelzusammensetzungen.
DE69014717D1 (de) Stabilisierte Zusammensetzungen von Metalloxidpulver.
ATE30008T1 (de) Stabilisierte zusammensetzung zur verwendung in pyrolytischer beschichtung von glas.
ES8505927A1 (es) Procedimiento para la preparacion de derivados de 1-(fenil)-1-hidroxi-2-amino-3-fluoro-propano
DE69112682D1 (de) Pfropfcopolymere zur Verwendung als Hauptkomponente von der Beschichtungszusammensetzung.
IT8347560A0 (it) Polipeptide dotato di attivita' di interferon, composizione che lo con tiene e procedimento di preparazione
Jixi et al. The spatial and temporal distributions of severe mesoscale convective systems over Tibetan Plateau in summer
AU8402491A (en) Beta chain of the human gm-csf receptor and uses thereof
ATE194381T1 (de) Alkoholhaltige instant-getränkemischung, ihre herstellung und verwendung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MURAMATSU, TAKASHI, NAGOYA, AICHI, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee